Ocular Therapeutix Appoints New Chief Medical Officer
Ticker: OCUL · Form: 8-K · Filed: Apr 18, 2024 · CIK: 1393434
| Field | Detail |
|---|---|
| Company | Ocular Therapeutix, Inc (OCUL) |
| Form Type | 8-K |
| Filed Date | Apr 18, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, personnel
Related Tickers: OCUL
TL;DR
OCUL names Dr. Miller as CMO, boosting clinical development focus.
AI Summary
Ocular Therapeutix, Inc. announced on April 14, 2024, the appointment of Dr. Jonathan T. Miller as Chief Medical Officer. Dr. Miller previously served as the company's Senior Vice President of Clinical Development. This appointment is part of the company's ongoing efforts to advance its ophthalmic drug development pipeline.
Why It Matters
The appointment of a new Chief Medical Officer can signal a strategic shift or increased focus on clinical development and regulatory pathways for the company's drug candidates.
Risk Assessment
Risk Level: low — The filing reports on an executive appointment, which is a routine corporate event with no immediate financial implications.
Key Players & Entities
- Ocular Therapeutix, Inc. (company) — Reporting company
- Dr. Jonathan T. Miller (person) — Appointed Chief Medical Officer
- April 14, 2024 (date) — Effective date of appointment
- Senior Vice President of Clinical Development (context) — Dr. Miller's previous role
FAQ
What is the effective date of Dr. Jonathan T. Miller's appointment as Chief Medical Officer?
Dr. Jonathan T. Miller's appointment as Chief Medical Officer was effective as of April 14, 2024.
What was Dr. Miller's previous role at Ocular Therapeutix?
Prior to his appointment as Chief Medical Officer, Dr. Miller served as the Senior Vice President of Clinical Development at Ocular Therapeutix.
What is the primary focus of Ocular Therapeutix?
Ocular Therapeutix is focused on developing and commercializing innovative therapies for ophthalmic conditions.
What is the company's principal executive office location?
The company's principal executive offices are located at 15 Crosby Drive, Bedford, MA 01730.
What is the Commission File Number for Ocular Therapeutix?
The Commission File Number for Ocular Therapeutix, Inc. is 001-36554.
Filing Stats: 1,016 words · 4 min read · ~3 pages · Grade level 10.4 · Accepted 2024-04-18 16:12:28
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share OCUL The Nasdaq
Filing Documents
- tm2412141d1_8k.htm (8-K) — 30KB
- tm2412141d1_ex99-1.htm (EX-99.1) — 3KB
- 0001104659-24-048850.txt ( ) — 203KB
- ocul-20240414.xsd (EX-101.SCH) — 3KB
- ocul-20240414_lab.xml (EX-101.LAB) — 33KB
- ocul-20240414_pre.xml (EX-101.PRE) — 22KB
- tm2412141d1_8k_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits: 99.1 Amendment No. 3 to 2019 Inducement Stock Incentive Plan 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. OCULAR THERAPEUTIX, INC. Date: April 18, 2024 By: /s/ Donald Notman Donald Notman Chief Financial Officer